Overview

A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

Status:
RECRUITING

Trial end date:
2027-01-03

Target enrollment:

Participant gender:

Summary

The main purpose of this study is to assess the ocular and systemic safety and tolerability of RO7669330 in GA secondary to AMD after multiple unilateral intravitreal (IVT) doses.

Phase:

PHASE1

Details

Lead Sponsor:

Hoffmann-La Roche

Treatments:

pegcetacoplan